Effectiveness of Focal Therapy Compared to Standard Radical Treatment in Men with Intermediate-Risk Prostate Cancer in the Netherlands
Led by Radboud University Medical Center · Updated on 2024-02-20
356
Participants Needed
5
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate focal therapy as a treatment option for men with intermediate-risk, unilateral clinically localized prostate cancer in the Netherlands. Traditional treatments like prostatectomy or radiotherapy often cause significant side effects such as incontinence and erectile dysfunction. Focal therapy targets only the cancerous part of the prostate, potentially reducing these side effects while maintaining cancer control. There is currently a lack of high-quality evidence supporting focal therapy, prompting this multi-center randomized controlled trial to assess its effectiveness, quality of life impact, and cost-effectiveness compared to usual care.
Participants will be randomly assigned to receive either focal therapy using devices like TULSA, irreversible electroporation IRE, or high-intensity focused ultrasound HIFU, or usual care involving radical prostatectomy or radiotherapy. Focal therapy involves treating only the affected prostate area while preserving the rest, with follow-up including MRI scans at 12, 24, 36, 48, and 60 months, prostate biopsies when indicated, and PSA monitoring. Usual care follows standard radical treatment protocols with PSA and imaging follow-up according to guidelines.
Throughout the study, participants will undergo regular assessments including PSA measurements, MRI scans, biopsies, and several quality of life questionnaires focusing on cancer-related, urinary, and sexual health outcomes. The main outcomes measured are treatment failure at 36 months and quality of life at 12 months. Secondary outcomes include metastasis-free survival, disease progression, mortality, adverse events, hospital stay, pathology results, and cost-effectiveness over 60 months. The trial includes intensive follow-up and safety monitoring, with a total participation timeline extending up to five years.
CONDITIONS
Brief Title
Effectiveness of Focal Therapy in Men With Prostate Cancer
Research Team
L
Lauren te Molder
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Prostate size of 5 cm or less in sagittal length and 6 cm or less in axial length
Fit and eligible for radical surgery or radiotherapy
No other active cancers
No previous treatment of the prostate
Sufficient understanding of Dutch language for trial information and questionnaires
You will not qualify if you...
Unfit for general anesthesia or radical surgery
Low volume low-risk prostate cancer (Gleason score 6 or less / ISUP grade 1)
High-risk prostate cancer (Gleason score 8 or higher / ISUP grade above 3)
Clinical T3 prostate cancer (extracapsular disease)
Prior active therapy for prostate cancer
Evidence of cancer spread outside the prostate
Inability to tolerate transrectal ultrasound
Presence of cardiac pacemaker
Metal implants or stents in urethra or prostate
ASA score of 4 or higher
Prostatic calcifications or cysts interfering with effective focal therapy delivery
Severe kidney impairment with glomerular filtration rate below 30 ml/min/1.73 m2
Unable to give informed consent as judged by clinicians
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - One-time intervention
Participants receive either focal therapy, a one-time procedure to selectively treat part of the prostate, or usual care including radical prostatectomy or radiotherapy.
1 treatment visit (in-person)
Follow-up
Duration - Up to 60 months
Participants undergo intensive follow-up with PSA measurements quarterly and yearly prostate MRI scans, along with biopsies at 12 months and as needed based on MRI findings, to monitor treatment effectiveness and side effects.
Quarterly visits for PSA measurement and yearly visits for MRI; biopsy at 12 months and if indicated
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of 177Lu-PSMA as an Additional Treatment for High and Very High Risk Prostate Cancer After Radiation and Hormone Therapy
Phase 1b Study of 177Lu-PSMA-617 With Liver-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer
Using 18F-PSMA-1007 PET-CT to Guide Targeted Focal Therapy for MRI-Invisible Prostate Cancer
A Prospective Phase II Study Evaluating PET-Directed Treatment in Men with Localized Intermediate-Risk Prostate Cancer
Evaluation of 18F-PSMA-1007 PETCT Imaging Safety and Effectiveness in Adult Men with Prostate Cancer
Combining One MR-Guided HDR Brachytherapy and One SABR Treatment
for Favorable Risk Prostate Cancer
in a Phase 23 Study
Study of 4-Aminopyridine to Improve Nerve Recovery After Robot-Assisted Radical Prostatectomy in Men with Prostate Cancer
Phase III Study of 64Cu-GRIP B PET Imaging for Detecting Granzyme B in Adults with Advanced Genitourinary and Other Solid Tumors
Comparison of 68Ga-P16-093 and 68Ga-PSMA-11 PETCT Scans for Detecting Primary Prostate Cancer in Men
Using 68Ga-PSMA PETMRI and mpMRI to Detect Prostate Cancer in Men Aged 40 to 85
Observational Study to Compare Diagnostic Accuracy and Follow-Up Outcomes
PETCT Imaging Using 68Ga-RM26-RGD to Detect Breast, Brain, and Prostate Tumors with GRPR and v3 Receptors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
Evaluation of Focal Ablation of Magnetic Resonance Imaging Defined Prostate Cancer Using Magnetic Resonance Imaging Controlled Transurethral Ultrasound Therapy with Prostatectomy as the Reference Standard.
Elizabeth Ramsay, Charles Mougenot, Robert Staruch...
Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.
Alexandar Blazevski, Matthijs J Scheltema, Brian Yuen...
Comparative Effectiveness Analyses of Salvage Prostatectomy and Salvage Radiotherapy Outcomes Following Focal or Whole-Gland Ablative Therapy (High-Intensity Focused Ultrasound, Cryotherapy or Electroporation) for Localised Prostate Cancer.
Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer.